Earlier today, Stellar Biotechnologies, Inc. (NASDAQ: SBOT)
(TSX-V: KLH) announced the presentation of a preclinical poster relating to its
ongoing research on Clostridium difficile. The poster, which was presented at
the Society for Glycobiology 2015 Annual Meeting in San Francisco, California,
reported data from the company’s studies into the potential development of C.
difficile cell surface polysaccharide-KLH conjugate vaccines, or active
immunotherapies, for the treatment of C. difficile infection.
Although C. difficile bacteria is normally present in the
intestine, it sometimes overgrows as a result of antibiotic use. The infection
that stems from this overgrowth has been linked to a host of dangerous side
effects – including severe diarrhea and life-threatening intestinal conditions,
such as colitis. Currently, the rate of U.S. cases of C. difficile overgrowth
is at an all-time high. According to a 2011 study by the Centers for Disease
Control and Prevention, C. difficile accounts for roughly 500,000 infections in
the U.S. each year, costing patients and insurers approximately $4.8 billion in
related medical expenses. Among those patients, an estimated 29,000 die within
30 days following initial diagnosis, further highlighting the importance of
Stellar’s research program.
Stellar is the global leader in the sustainable manufacture
of keyhole limpet hemocyanin (KLH) protein, which is an important
immune-stimulating molecule widely used as an active pharmaceutical ingredient
in immunotherapies. As a result of its proprietary method of sustainably
producing GMP grade KLH, the company has partnered with a host of multinational
pharmaceutical firms, renowned research centers and developers of active
immunotherapies and therapeutic vaccines to address critically underserved
indications in the biopharmaceutical industry.
Last month, the company successfully leveraged the
marketability of its KLH protein by uplisting to the NASDAQ Capital Market.
Following this move, Stellar reiterated intentions to expand its manufacturing
capacity in order to better address the growing demand for KLH protein in
immunotherapy. For prospective shareholders, the company’s recent progress
represents an important step toward achieving sustainable corporate growth in
the months to come.
To view the poster, Clostridium difficile Surface
Polysaccharide-KLH Conjugate Vaccine Induced Th17-Featured Adaptive Immune
Responses in Mice, visit
http://content.equisolve.net/stellarbiotechnologies/media/0e37609debe1b998c4ccef5dd2a84a82.pdf
For more information, visit www.stellarbiotech.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
